Exact Sciences Corporation is a molecular diagnostics company dedicated to changing the way cancer is detected and diagnosed, focusing on delivering innovative solutions for cancer screening and diagnostics. The company operates primarily through two main segments: Screening Products and Diagnostic Services, each equipped with unique offerings that serve the healthcare market.
Segments:
1. Screening Products: Exact Sciences has carved out a niche in the colorectal cancer screening landscape with its non-invasive solutions, designed for patient accessibility and comfort.
- Cologuard: This flagship product represents a significant advancement in colorectal cancer screening. Cologuard is a non-invasive, multi-target stool DNA test that detects certain DNA mutations and the presence of blood in stool samples, indicating potential colorectal cancer or pre-cancerous polyps. It stands out for its ease of use, allowing patients to complete the test in the privacy of their own homes without the need for an invasive procedure, dietary restrictions, or bowel preparation. Clinical studies indicate Cologuard has a high sensitivity rate of 92% for detecting colorectal cancer and 69% for detecting high-risk pre-cancerous polyps. Additionally, it is FDA-approved and widely covered by major health insurance plans, enhancing its accessibility for patients.
Diagnostic Services: Through its subsidiary, Exact Diagnostics, the company extends its offerings into a broad array of diagnostic testing across various disease states.
- Oncotype DX: This genomic test analyzes the expression of multiple genes within a tumor tissue sample to provide insights into the likelihood of breast cancer recurrence and the effectiveness of chemotherapy. It generates a risk score, enabling oncologists to tailor treatment plans more accurately based on individual tumor biology. Notably, this test has applications beyond breast cancer, including other oncological assessments.
- OncoBlot: This innovative blood test detects specific tumor-associated proteins circulating in the bloodstream. By identifying these biomarkers, OncoBlot can aid in the early detection of diverse cancers, such as lung, prostate, breast, and colorectal cancers. This test is valuable in the clinical setting for both diagnosis and monitoring of disease progression or recurrence.
- COVID-19 Testing: In response to the global pandemic, Exact Sciences has developed molecular diagnostic testing for COVID-19. This test, which is FDA-approved and CLIA-certified, detects the presence of the SARS-CoV-2 virus in respiratory samples, such as nasal swabs and saliva. This offering not only underscores the companys flexibility and responsiveness to emerging health crises but also provides significant value in pandemic management.
Products:
1. Cologuard: As mentioned, this test is pivotal for colorectal cancer screening and enhances early detection. Its non-invasive nature, combined with high sensitivity and accuracy, positions it as a leading choice in this realm.
2. Oncotype DX: This products capability to offer personalized medicine insights through genomic testing is instrumental in shaping treatment decisions, making it a critical tool for oncologists in managing breast cancer and potentially other malignancies.
3. OncoBlot: By serving as a general cancer screening test, OncoBlot opens avenues for early intervention across various cancer types, which can fundamentally alter patient outcomes.
4. COVID-19 Testing: By offering effective and rapid COVID-19 testing solutions, Exact Sciences showcases its agility in addressing urgent public health needs, reinforcing its reputation in the diagnostics sector.
Services:
1. Diagnostic Testing Services: The company’s offerings extend into comprehensive diagnostic testing services, which include genetic, oncology, and infectious disease testing. The testing aims to deliver accurate and timely diagnostic information that helps healthcare professionals in making well-informed decisions regarding patient care options.
2. Patient Support Services: Exact Sciences recognizes the importance of supporting patients throughout their testing process. It provides a robust range of patient support services for individuals using Cologuard, which includes access to live representatives who assist with queries, insurance reimbursement navigation, and educational resources. Additionally, a patient portal enables users to conveniently access their results and effectively manage their screening process online.
Through these extensive and innovative products and services, Exact Sciences Corporation is at the forefront of advancing early cancer detection and diagnosis, driving improvements in patient care, and enhancing outcomes across a range of cancer types. By leveraging cutting-edge technology and a patient-centric approach, the company is positioning itself as a leader in the molecular diagnostics landscape.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
78.39 %